Gladius Capital Management LP Acumen Pharmaceuticals, Inc. Transaction History
Gladius Capital Management LP
- $99.2 Million
- Q2 2024
A detailed history of Gladius Capital Management LP transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Gladius Capital Management LP holds 10,939 shares of ABOS stock, worth $31,613. This represents 0.03% of its overall portfolio holdings.
Number of Shares
10,939Holding current value
$31,613% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding ABOS
# of Institutions
84Shares Held
41.8MCall Options Held
239KPut Options Held
65.9K-
Ra Capital Management, L.P. Boston, MA14.9MShares$43.2 Million0.54% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$9.88 Million4.16% of portfolio
-
Franklin Resources Inc San Mateo, CA3.37MShares$9.73 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.3MShares$6.65 Million0.17% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$6.24 Million0.0% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $117M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...